Proactive Investors - Run By Investors For Investors

Silence Therapeutics makes key new hire

Giles Campion has been appointed head of research and development and chief medical officer
Silence Therapeutics makes key new hire
Chief executive David Horn Solomon said Campion would be a valuable addition to the management team

Silence Therapeutics PLC (LON:SLN) has appointed industry veteran Giles Campion as head of research and development and the company’s chief medical officer.

He occupied the same roles at Prosensa, which was acquired by Biomarin in 2015 for US$680mln and, in his 20-year career, he also held senior R&D roles at the Swiss giant Novartis (NYSE:NVS). He holds a medical degree and doctorate from Bristol University.

READ: Silence Therapeutics makes clinical trial application for lead drug

“Giles is a valuable addition to the management team and his expertise will help the company to deliver on its core mission of tackling the unmet medical needs of patients suffering from rare conditions," said Silence chief executive David Horn Solomon.

Campion joins the company on June 1

In a later announcement, Silence also said the search for a permanent chairman continues after announcing that interim chair, Dr Andy Richards, had stepped down with immediate effect.

 -- Adds chairman's departure --

View full SLN profile View Profile

Silence Therapeutics PLC Timeline

Related Articles

tablets and pills
June 27 2019
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
cannabis
February 28 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use